| Literature DB >> 29924454 |
Yuzo Harada1, Shinsuke Kazama1,2, Teppei Morikawa3, Shigenobu Emoto1, Koji Murono1, Manabu Kaneko1, Kazuhito Sasaki1, Kensuke Otani1, Takeshi Nishikawa1, Toshiaki Tanaka1, Tomomichi Kiyomatsu1, Kazushige Kawai1, Keisuke Hata1, Hiroaki Nozawa1, Soichiro Ishihara1,4, Toshiaki Watanabe1.
Abstract
Preoperative chemoradiotherapy (CRT) is a standard therapy for locally advanced rectal cancer; however, the response varies depending on cases. Therefore, CRT-response predictors need to be elucidated. Cancer stem cells (CSCs), comprising a small part of tumors, are associated with tumor progression and recurrence due to their self-renewal and proliferation abilities. Doublecortin-like kinase 1 (DCLK1) is one of the several putative CSC markers; however, the clinical impact of its expression in rectal cancer has not been evaluated. The aim of this study was to clarify the clinical impact of DCLK1 expression in rectal cancer. We immunohistochemically evaluated DCLK1 expression in surgical specimens of 106 rectal cancer patients, including those who underwent preoperative CRT. The correlations between DCLK1 expression, and clinicopathological features and patient prognosis were then assessed. In rectal cancer patients treated with preoperative CRT, DCLK1 expression was significantly correlated with lymph node metastasis (p = 0.02) and poor cancer-specific survival (p = 0.049). However, in patients treated without preoperative therapy, no such correlation was found. DCLK1 expression can be associated with lymph node metastasis and poor cancer-specific survival in rectal cancer patients who receive CRT.Entities:
Keywords: DCLK1; chemoradiotherapy; immunohistochemistry; rectal cancer
Mesh:
Substances:
Year: 2018 PMID: 29924454 DOI: 10.1111/apm.12852
Source DB: PubMed Journal: APMIS ISSN: 0903-4641 Impact factor: 3.205